Cargando…
Epigenetic engineering for optimal chimeric antigen receptor T cell therapy
Recent advancements in cancer immunotherapy, such as chimeric antigen receptor (CAR)‐engineered T cell therapy and immune checkpoint therapy, have significantly improved the clinical outcomes of patients with several types of cancer. To broaden its applicability further and induce durable therapeuti...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633293/ https://www.ncbi.nlm.nih.gov/pubmed/36000807 http://dx.doi.org/10.1111/cas.15541 |